Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 2, 2013, Pages 357-367

  Gallardo, Enrique ^a   Arranz, José Ángel ^b   Maroto, José Pablo ^c   León, Luis Ángel ^d   Bellmunt, Joaquim ^e  

^a HOSPITAL DE SABADELL   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d University Hospital of Santiago de Compostela   (Spain)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

Algorithm; Cabazitaxel; Castration resistant hormone cancer; Consensus; Docetaxel

Indexed keywords

ABIRATERONE; ALBUMIN; ALKALINE PHOSPHATASE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; LACTATE DEHYDROGENASE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

AGE; ALGORITHM; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ASTHENIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMORBIDITY; CONSENSUS; DIARRHEA; DISEASE ACTIVITY; EVIDENCE BASED MEDICINE; FLUID RETENTION; FUNCTIONAL STATUS; GLEASON SCORE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIVER TOXICITY; MEDICAL EXPERT; NEUTROPENIA; RETREATMENT; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VISCERAL METASTASIS;

ALGORITHM; CABAZITAXEL; CASTRATION-RESISTANT HORMONE CANCER; CONSENSUS; DOCETAXEL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; EXPERT TESTIMONY; HUMANS; MALE; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84885853626     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.06.008     Document Type: Review

References (39)

1. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 2008, 26:1148-1159.
2. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 2004, 351:1502-1512.
3. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010, 376:1147-1154.
4. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 2011, 364:1995-2005.
5. Scher H.I., Fizazi S.K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 2012, 367:1187-1197.
6. Parker C., Nilsson S., Heinrich D., et al. Updated analysis of the phase III, double-blind, randomized multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). Journal of Clinical Oncology 2012, 30. [suppl; abstr LBA 4512].
7. Droz J.P., Balducci L., Bolla M., et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU International 2010, 106:462-469.
8. Mulders P.F.A., Molina A., Marberger M., et al. Improved survival in elderly (75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study. European Urology Supplements 2012, 11(1):e127. [abstr 127].
9. Heidenreich A., Bracarda S., Mason M., et al. Tolerability of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer (MCRPC) in Europe. Annals of Oncology 2012, 23. [suppl 9; abstr 932P].
10. Sartor A.O., Oudard S., Ozguroglu M., et al. Prognostic factors for survival in the phase III TROPIC study. Journal of Clinical Oncology 2012, 30. [suppl 5; abstr 102A].
11. Jevtana (cabazitaxel) Summary of product characteristics; 2012. Available from: [accessed 24.06.12]. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR__Product_Information/human/002018/WC500104764.pdf.
12. Fizazi K., Scher H.I., Molina A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncology 2012, 13:983-992.
13. Halabi S., Vogelzang N.J., Ou S.S., et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. Journal of Clinical Oncology 2009, 27:2766-2771.
14. Penney K.L., Sinnott J.A., Fall K., et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. Journal of Clinical Oncology 2011, 29:2391-2396.
15. Ross R.W., Xie W., Regan M.M., et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008, 112:1247-1253.
16. Azria D., Massard C., Tosi D., et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response. Journal of Clinical Oncology 2012, 30. [suppl 5; abstr 149].
17. Oudard S., de Bono J.S., Ozguroglu M., et al. Impact of cabazitaxel (CBZ)+prednisone (P; CBZP)on overall survival (OS) at 2 yrs and in patients with aggressive disease: post-hoc analyses of TROPIC trial. Annals of Oncology 2012, 23. [suppl 9; abstr 933P].
18. Fizazi K., Massard C., Smith M.R., et al. Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer. Journal of Clinical Oncology 2012, 30. [suppl; abstr 4642].
19. Sabbatini P., Larson S.M., Kremer A., et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 1999, 17:948-957.
20. Halabi S., Vogelzang N.J., Kornblith A.B., et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. Journal of Clinical Oncology 2008, 26:2544-2549.
21. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clinical Cancer Research 2007, 13:6396-6403.
22. Oudard S., Banu E., Scotte F., et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Annals of Oncology 2007, 18:1828-1833.
23. Armstrong A.J., Eisenberger M.A., Halabi S., et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. European Urology 2011, 61:549-559.
24. Leibovici D., Spiess P.E., Agarwal P.K., et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007, 109:198-204.
25. Sonpavde G., Pond G.R., Berry W.R., et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology 2012, 30(5):607-613.
26. Armstrong A.J., Garrett-Mayer E., de Wit R., Tannock I., Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research 2010, 16:203-211.
27. Sonpavde G., Pond Gr Berry W.R., de Wit R., et al. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer 2011, 17:3963-3971.
28. Hussain M., Goldman B., Tangen C., et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. Journal of Clinical Oncology 2009, 27:2450-2456.
29. Loriot Y., Massard C., Albiges A., et al. Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. Journal of Clinical Oncology 2012, 30. [suppl 5; abstr 213].
30. Danila D.C., Morris M.J., de Bono J.S., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology 2010, 28:1496-1501.
31. Ryan C.J., Li J., Kheoh T., Scher H.I., Molina A. Baseline serum adrenal androgens are prognostic and predictive of overall survival in patients with metastatic castrate-resistant prostate cáncer: results from the COU-AA-301 phase 3 randomized trial. Proceedings of the103rd Annual Meeting of the American Association for Cancer Research (AACR) 2012, [abstract LB-434].
32. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Journal of National Cancer Institute 2006, 98:516-521.
33. Armstrong A.J., Garrett-Mayer E., Ou Yang Y.O., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology 2007, 25:3965-3970.
34. Chi K.N., Scher H.I., Molina A., et al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2012, 30. [suppl 5; abstr 15].
35. Mukherji D., Pezaro C.J., Bianchini D., Zivi A., de Bono J.S. Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel. Journal of Clinical Oncology 2012, 30. [suppl 5; abstr 17].
36. Pond G.R., Armstrong A.J., Wood B.A., et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European Urology 2012, 61:363-369.
37. Mauch P., Constine L., Greenberger J., et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. International Journal of Radiation Oncology Biology Physics 1995, 31:1319-1339.
38. Climent M.A., Piulats J.M., Sánchez-Hernández A., et al. Recommendations from the Spanish Oncology Genitorurinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Critical Reviews in Oncology/Hematology 2012, 83(3):341-352.
39. Buonerba C., Palmieri G., Di Lorenzo G. Docetaxeol rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. European Urology 2010, 58(4):636-637.